Arrowhead Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $3,551 |
Gross Profit | -4,782 | -4,525 | -712 | |
EBITDA | -153,126 | -164,101 | -115,227 | -129,059 |
EBIT | -158,151 | -168,883 | -119,752 | -133,322 |
Net Income | -170,536 | -170,793 | -125,300 | -132,864 |
Net Change In Cash | 0 | 0 | 0 | 3,551 |
Free Cash Flow | -161,505 | -129,867 | -126,452 | -186,496 |
Cash | 102,685 | 69,399 | 127,704 | 58,215 |
Basic Shares | 124,478 | 124,199 | 123,285 | 107,415 |
Annual Financials
| Values in thousands | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|
Revenue | $3,551 | $240,735 | $243,231 | $138,287 |
Gross Profit | 3,551 | 240,735 | 243,231 | 138,287 |
EBITDA | -561,513 | -175,672 | -168,086 | -132,580 |
EBIT | -580,108 | -188,165 | -178,507 | -140,846 |
Net Income | -599,493 | -205,275 | -176,494 | -140,848 |
Net Change In Cash | 3,551 | 240,735 | 243,231 | 138,287 |
Cost of Revenue | -76,362 | 40,851 | ||
Free Cash Flow | -604,320 | -330,627 | -188,908 | 147,657 |
Cash | 102,685 | 110,891 | 108,005 | 184,434 |
Basic Shares | 119,784 | 106,750 | 105,426 | 103,745 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$1.37 |
2024-06-30 | -$1.38 |
2024-03-31 | -$1.02 |
2023-12-31 | -$1.24 |
